Summary of Clinical Use

May have potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma. For further details of a relevant clinical trial (NCT0099691) click here, but note that this study was terminated because two large Phase 3 studies showed no clinical benefit associated with antibody treatment. The lack of effect in these Phase 3 trials is reported in the Jan 23 (2014) issue of the New England Journal of Medicine [3]. These trials did report some reduction in amyloid β (Aβ) build up in the patients receiving the drug, suggesting that it may be more useful as a preventative treatment in patients at risk of developing Alzheimer's disease, as once the Aβ plaques have formed it may be too late to reverse their effects.